
|Videos|December 17, 2021
Current developments in PSMA research
Author(s)Urology Times staff
“I believe we are getting to an era where we will be able to cure a significant subset of patients who we are not able to cure today,” says Neil H. Bander, MD.
Advertisement
In this video, Neil H. Bander, MD, shares his perspective on what the future of prostate-specific membrane antigen (PSMA) research will look like as well as what current developments are taking place. Bander is the Bernard & Josephine Chaus professor of urologic oncology at Weill Cornell Medicine, New York City, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
Choosing salvage therapy after prostate cancer focal ablation
4
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
5

















